Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement

Revive Therapeutics

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, April 15, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that further to its press releases of Februar... Read More...

1 views5 min read

Revive Therapeutics Announces Filing of FDA Pre-IND Meeting

Revive Therapeutics

TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, announced today that it has filed its Pre-Investigational New Drug (“pre-IND”) meeting request with the U.S. Food and Drug Ad... Read More...

1 views1 min read

Investor Announcement

Revive Therapeutics

TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these materials... Read More...

1 views14 min read

Revive Therapeutics Provides Corporate Update on its COVID-19 and Infectious Diseases Programs

Revive Therapeutics

TORONTO, March 30, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, is pleased to provide a corporate update on its plans for the Company’s coronavirus disease (“COVID-19”) and infectious disea... Read More...

1 views5 min read

Revive Therapeutics Engages Pharma-Olam and Strengthens Infectious Diseases Clinical Development Team to Advance U.S. FDA Clinical Study for COVID-19

Revive Therapeutics

TORONTO, March 25, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC, with proven clinical experience in infectious diseases ... Read More...

1 views4 min read

Revive Therapeutics Appoints Dr. David Boulware, MD, as Scientific Advisor for Infectious Diseases including COVID-19

Revive Therapeutics

TORONTO, March 24, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that Dr. David Boulware, MD, MPH, CTropMed, FIDSA, will join the Company as a Scientific Advisor to guide on the Company’s current and future clinical programs including its research and development st... Read More...

1 views6 min read

Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

Revive Therapeutics

TORONTO, March 20, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, is pleased to announce that it is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (COVID-19). The Company has applied for a pro... Read More...

16 views4 min read

Revive Therapeutics Announces Closing of Brokered Private Placement

Revive Therapeutics

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, March 18, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a cannabis and psychedelic life sciences company, is pleased to announce that further to its ... Read More...

M & A2 views5 min read

Revive Announces Closing of the Acquisition of Psilocin Pharma Corp.

Revive Therapeutics

TORONTO, March 05, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products, is pleased to announce that, further to its press release of February 12, 2020, the Company has completed its acquisition o... Read More...

1 views4 min read

Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis

Revive Therapeutics

TORONTO, Feb. 18, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a company focused on the research, development and commercialization of novel cannabinoid-based and life sciences products, is pleased to provide an update on the Company’s clinical development plan for Cannabidiol (“CBD”) in the treatment of Autoimmune Hepati... Read More...

LOIM & A1 views4 min read

Revive Enters into Psychedelics Market with Letter of Intent to Acquire Psilocin Pharma Corp.

Revive Therapeutics

TORONTO, Feb. 12, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) is pleased to announce that it has entered into a letter of intent, dated February 11, 2020 (the “LOI”) with Psilocin Pharma Corp. (“Psilocin”), an arm’s length party incorporated pursuant to the laws of the Province of Ontario. Pursuant to the terms of the LOI... Read More...

1 views4 min read

Revive Therapeutics Announces Brokered Private Placement of up to $2 million

Revive Therapeutics

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREINTORONTO, Feb. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory dis... Read More...

1 views2 min read

Revive Therapeutics to Pursue the Psychedelic Market With Agreement and Investment in Red Light Holland Financing

Revive Therapeutics

TORONTO, Feb. 10, 2020 -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has entered into a supply and collaboration agreement (the “Agreement”) with Red Light Holland Financing Inc. (“Red Light”), an arm’s l... Read More...

1 views2 min read

Revive Therapeutics Announces Offering of $210,000 of Convertible Debenture Units

Revive Therapeutics

TORONTO, Feb. 05, 2020 -- Revive Therapeutics Ltd. (“Revive”), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to announce that it has issued 210,000 secured convertible debenture units (the “Debenture Units”) to arm’s length parties for aggregate gross proceeds of ... Read More...

1 views3 min read

Revive Therapeutics Provides Update on its Cannabinoid Program Initiatives for Drug Delivery and in the Prevention of Ischemia and Reperfusion Injury from Organ Transplantation

Revive Therapeutics

TORONTO, Jan. 20, 2020 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE:RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update, further to the Company’s announcement on January 6, 2020 regarding its clinical development plan on liver... Read More...

1 views6 min read

Revive Therapeutics Provides Update on its Clinical Development Plan For Rare Liver Diseases

Revive Therapeutics

TORONTO, Jan. 06, 2020 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE:RVV), a cannabis life sciences company focused on novel cannabinoid-based treatments for rare inflammatory diseases, is pleased to provide an update on the Company’s clinical development plan for Autoimmune liver diseases, which includes Cannabidiol in th... Read More...

1 views1 min read

Revive Therapeutics Announces Grant of Stock Options

Revive Therapeutics

TORONTO, Dec. 27, 2019 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE:RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, announces a grant of incentive stock options to its newly-constituted Board of Directors, totalling 4.3 million at an e... Read More...

1 views5 min read

Revive Therapeutics Provides Update on its Cannabis-based Pharmaceutical Initiatives

Revive Therapeutics

TORONTO, Dec. 19, 2019 -- Revive Therapeutics Ltd. (“Revive” and the “Company”) (CSE:RVV), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to provide an update on its cannabis-based pharmaceuticals initiatives in its objective in offering novel th... Read More...

1 views6 min read

Revive Therapeutics Announces New Leadership Appointment and Board Change

Revive Therapeutics

TORONTO, Dec. 18, 2019 -- Revive Therapeutics Ltd. (“Revive" and the “Company") (CSE:RW), a cannabis life sciences company focused on the research, development, and commercialization of novel cannabinoid-based products, is pleased to announce that all the resolutions put forward by the Company at its annual general meeting of shareholders... Read More...

rvv